A Compassionate Use (CU) Program of Odronextamab
Primary Purpose
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL)
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Odronextamab
Sponsored by
About this trial
This is an expanded access trial for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT05619367
First Posted
November 8, 2022
Last Updated
July 7, 2023
Sponsor
Regeneron Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT05619367
Brief Title
A Compassionate Use (CU) Program of Odronextamab
Study Type
Expanded Access
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
Provide compassionate use of odronextamab
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL)
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Odronextamab
Other Intervention Name(s)
REGN1979
10. Eligibility
Sex
All
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Requests for compassionate use must be initiated by a treating physician Physicians should contact
Phone
844-734-6643
Email
CompassionateUseRequests@regeneron.com
12. IPD Sharing Statement
Learn more about this trial
A Compassionate Use (CU) Program of Odronextamab
We'll reach out to this number within 24 hrs